Uni-Bio Science

14 articles about Uni-Bio Science

• Uni-Bio Science Group Limited 2019 Interim Results Successful Turning Loss into Profit, Strong Release of Market Potential Sales of key products doubled, Business restructuring completed smoothly

  8/30/2019

  A fully integrated biopharmaceutical company - Uni-Bio Science Group Limited are pleased to announce that its interim results for the period ended 30 June 2019

• Uni-Bio Science (HK690) Appoints CEO, Non-Executive Director and Independent Non-executive Director Leveraging on Deep Industry Knowledge to Garner New Impetus

  4/9/2019

  Uni-Bio Science Group Limited is pleased to announce the appointment of Mr. Zhao Zhi Gang as the CEO, Mr. Ma Qing Shan as independent non-executive director and Mr. Tony Yau as non-executive director of the Group, effective on 8 April 2019.

• Uni-Bio Science Group (0690.HK) - 2018 Annual Results Enhanced Market Penetration of Core Marketed Products Pipeline Products Witnessed a Steady Progress to Launch Commencement of CMO Service to Fully Harness Asset Values

  3/29/2019

  A fully integrated biopharmaceutical company - Uni-Bio Science Group Limited, is pleased to announce its annual results for the year ended 31 December 2018, as well as its comparatively figures for the year ended 31 December 2017.

• Cedrus Reiterated Overweight Rating on Uni-Bio Science Group Limited with a June 2019 Price Target of HKD0.28

  8/22/2018

  Cedrus Investments issued a company update report on Uni-Bio Science Group Limited ("Uni-Bio Science" or "the Group") (stock code: 0690) on 21 August 2018.

• Mr. Winston Xue, General Manager of Uni-Bio Science Healthcare Limited Was Interviewed by Bioon.com

  6/5/2018

  Shared on the Transformation of a Hong Kong Based Innovative Enterprise

• Uni-Bio Science Group Limited Posts Its 2017 Annual Results

  3/30/2018

  Restructured Marketing and Sales Platform to Enhance Competitive Advantage

• Uni-Bio Science Raises $18.2 Million; Partners With HeungKong Group

  7/20/2017

• Uni-Bio Science Launches Oral Type 2 Diabetes Drug In China

  5/8/2017

• Uni-Bio Science Launches Best-in-Class Oral Anti-Diabetic Drug Mitiglinide Branded Bokangta

  5/5/2017

• Uni-Bio Science In Multiple Drug Co-Development Deal With Beijing Sun-Novo

  12/2/2016

• Uni-Bio Forges Strategic Alliance With Luqa Pharmaceuticals

  11/15/2016

• Uni-Bio Signs Up CR Zizhu To Market Recombinant Eye Treatment In China

  7/15/2016

• Uni-Bio Files For China Approval Of Novel Osteoporosis Drug

  4/24/2015

• Uni-Bio to Begin Phase III Trial of Diabetes Drug

  7/13/2009